RU2017114109A - Кристаллические модификации элобиксибата - Google Patents
Кристаллические модификации элобиксибата Download PDFInfo
- Publication number
- RU2017114109A RU2017114109A RU2017114109A RU2017114109A RU2017114109A RU 2017114109 A RU2017114109 A RU 2017114109A RU 2017114109 A RU2017114109 A RU 2017114109A RU 2017114109 A RU2017114109 A RU 2017114109A RU 2017114109 A RU2017114109 A RU 2017114109A
- Authority
- RU
- Russia
- Prior art keywords
- elobixibate
- crystalline
- dihydrate
- liver
- anhydrous
- Prior art date
Links
- XFLQIRAKKLNXRQ-UUWRZZSWSA-N elobixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C=3C=CC=CC=3)C=C2S(=O)(=O)CC(CCCC)(CCCC)CN1C1=CC=CC=C1 XFLQIRAKKLNXRQ-UUWRZZSWSA-N 0.000 title 1
- 229950000820 elobixibat Drugs 0.000 title 1
- 108010007192 elobixibat Proteins 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 150000004683 dihydrates Chemical class 0.000 claims 14
- 206010010774 Constipation Diseases 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 230000005855 radiation Effects 0.000 claims 6
- 206010008635 Cholestasis Diseases 0.000 claims 5
- 238000002441 X-ray diffraction Methods 0.000 claims 5
- 230000007870 cholestasis Effects 0.000 claims 4
- 231100000359 cholestasis Toxicity 0.000 claims 4
- 210000004185 liver Anatomy 0.000 claims 4
- 208000019423 liver disease Diseases 0.000 claims 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000001771 impaired effect Effects 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 210000000941 bile Anatomy 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 210000000013 bile duct Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 230000007803 itching Effects 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 201000011374 Alagille syndrome Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010004637 Bile duct stone Diseases 0.000 claims 1
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 claims 1
- 201000009331 Choledocholithiasis Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 229940125922 IBAT inhibitor Drugs 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010065973 Iron Overload Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000017855 Progressive familial intrahepatic cholestasis type 1 Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010048215 Xanthomatosis Diseases 0.000 claims 1
- 201000004525 Zellweger Syndrome Diseases 0.000 claims 1
- 208000036813 Zellweger spectrum disease Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000009866 extrahepatic cholestasis Diseases 0.000 claims 1
- 230000004129 fatty acid metabolism Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 208000016245 inborn errors of metabolism Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 201000002162 progressive familial intrahepatic cholestasis 1 Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14190290.8 | 2014-10-24 | ||
| EP14190290.8A EP3012252A1 (en) | 2014-10-24 | 2014-10-24 | Crystal modifications of elobixibat |
| PCT/EP2015/074573 WO2016062848A1 (en) | 2014-10-24 | 2015-10-23 | Crystal modifications of elobixibat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017114109A true RU2017114109A (ru) | 2018-11-26 |
| RU2017114109A3 RU2017114109A3 (enExample) | 2019-04-30 |
Family
ID=51786891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017114109A RU2017114109A (ru) | 2014-10-24 | 2015-10-23 | Кристаллические модификации элобиксибата |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10183920B2 (enExample) |
| EP (3) | EP3012252A1 (enExample) |
| JP (1) | JP6700263B2 (enExample) |
| KR (1) | KR102498539B1 (enExample) |
| CN (2) | CN107001301A (enExample) |
| AU (1) | AU2015334883B2 (enExample) |
| CA (1) | CA2959760C (enExample) |
| ES (1) | ES2874573T3 (enExample) |
| RU (1) | RU2017114109A (enExample) |
| WO (1) | WO2016062848A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201800453T1 (it) | 2010-11-04 | 2018-11-09 | Albireo Ab | Inibitori di ibat per il trattamento delle epatopatie |
| JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Ｅａファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| KR101844184B1 (ko) * | 2017-07-21 | 2018-04-02 | 씨제이헬스케어 주식회사 | 아미노알킬벤조티아제핀 유도체의 용도 |
| CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| TWI823573B (zh) * | 2018-03-09 | 2023-11-21 | 瑞典商依洛比克斯公司 | 用於製備1,5-苯并噻氮呯化合物之方法 |
| US10428109B1 (en) | 2018-03-09 | 2019-10-01 | Elobix Ab | Process for the preparation of 1,5-benzothiazepine compounds |
| TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| FI3810581T3 (fi) | 2018-06-20 | 2025-02-28 | Albireo Ab | Odeviksibaatin kiteiset modifikaatiot |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| ES2937153T3 (es) | 2019-02-06 | 2023-03-24 | Albireo Ab | Compuestos de benzotiadiazepinas y su uso como moduladores de ácidos biliares |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| WO2021049311A1 (ja) * | 2019-09-09 | 2021-03-18 | エロビクス・アーベー | １，５－ベンゾチアゼピン化合物を製造するための方法 |
| ES2973355T3 (es) | 2019-12-04 | 2024-06-19 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| KR20220109450A (ko) | 2019-12-04 | 2022-08-04 | 알비레오 에이비 | 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의 이의 용도 |
| CN114761018B (zh) | 2019-12-04 | 2025-12-02 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CA3158276A1 (en) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3186857A1 (en) | 2020-08-03 | 2022-02-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| WO2022101379A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| CN116583504A (zh) | 2020-12-04 | 2023-08-11 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| CN117980295A (zh) * | 2022-08-02 | 2024-05-03 | 上海皓元医药股份有限公司 | 一种依洛西巴特晶型ii及其制备方法 |
| AU2023374724A1 (en) | 2022-11-03 | 2025-05-01 | Albireo Ab | Treating alagille syndrome (algs) |
| WO2025093760A1 (en) | 2023-11-03 | 2025-05-08 | Albireo Ab | Treating pfic2 with odevixibat |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539380A (en) | 1968-01-08 | 1970-11-10 | Upjohn Co | Methylcellulose and polyalkylene glycol coating of solid medicinal dosage forms |
| GB1530201A (en) | 1976-04-14 | 1978-10-25 | Pfizer Ltd | Process for the preparation of aminoglycoside antibiotics and intermediates therefor |
| GB1566609A (en) | 1977-03-10 | 1980-05-08 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions containing cholestyramine and alginic acid |
| EP0019115B1 (de) | 1979-04-30 | 1983-01-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pankreozymin-Cholezystokinin aktive Peptide, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel |
| US4900757A (en) | 1988-12-08 | 1990-02-13 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane |
| IL95574A (en) | 1989-09-09 | 1994-11-11 | Knoll Ag | Colestyramine preparation |
| DE3930168A1 (de) | 1989-09-09 | 1991-03-14 | Knoll Ag | Verbesserte verabreichungsform fuer colestyramin |
| ATE144988T1 (de) | 1990-12-06 | 1996-11-15 | Hoechst Ag | Gallensäurederivate, verfahren zu ihrer herstellung und verwendung dieser verbindung als arzneimittel |
| FI108451B (fi) | 1991-12-20 | 2002-01-31 | Hoechst Ag | Menetelmõ polymeeristen ja oligomeeristen sappihappojohdannaisten valmistamiseksi |
| JPH05186357A (ja) | 1991-12-31 | 1993-07-27 | Shigeo Ochi | 飲食物消化分解産物吸収抑制手段 |
| GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| IT1257793B (it) | 1992-05-18 | 1996-02-13 | Composizione farmaceutica a base di acidi biliari in microgranuli a rilascio controllato | |
| ES2111092T3 (es) | 1992-06-12 | 1998-03-01 | Hoechst Ag | Derivados de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos. |
| US5350584A (en) | 1992-06-26 | 1994-09-27 | Merck & Co., Inc. | Spheronization process using charged resins |
| IL108633A (en) | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| DE69425453T2 (de) | 1993-04-23 | 2001-04-12 | Novartis Ag, Basel | Wirkstoffabgabevorrichtung mit gesteuerter Freigabe |
| TW289757B (enExample) | 1993-05-08 | 1996-11-01 | Hoechst Ag | |
| TW289021B (enExample) | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
| EP0624593A3 (de) | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
| TW289020B (enExample) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
| ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| PT781278E (pt) | 1994-09-13 | 2001-08-30 | Monsanto Co | Novas benzotiepinas com actividade inibidora do transporte de acido biliar ileal e da remocao do taurocolato |
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US5994391A (en) | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
| US5811388A (en) | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| ATE293883T1 (de) | 1996-01-16 | 2005-05-15 | Ronald J Sokol | Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen |
| JP2001526627A (ja) | 1996-03-11 | 2001-12-18 | ジー．ディー．サール アンド カンパニー | 回腸胆汁酸輸送及びタウロコール酸塩吸収の阻害剤としての活性を有する新規ベンゾチエピン類 |
| WO1998003818A1 (de) | 1996-07-24 | 1998-01-29 | Zumtobel Staff Gmbh | Adapter für ein haltemittel, welches zum befestigen einer einbauleuchte in einer einbauöffnung bestimmt ist, oder haltemittel oder einbauleuchte mit einem solchen adapter |
| DE19633268A1 (de) | 1996-08-19 | 1998-02-26 | Hoechst Ag | Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung |
| GB9704208D0 (en) | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
| NZ337830A (en) | 1997-03-11 | 2001-07-27 | G | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| DE69815180T2 (de) | 1997-03-14 | 2004-04-29 | Aventis Pharma Deutschland Gmbh | Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| AUPO763197A0 (en) | 1997-06-30 | 1997-07-24 | Sigma Pharmaceuticals Pty Ltd | Health supplement |
| WO1999032478A1 (en) | 1997-12-19 | 1999-07-01 | G.D. Searle & Co. | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides |
| GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
| JP2002513013A (ja) | 1998-04-24 | 2002-05-08 | 藤沢薬品工業株式会社 | グアニジン誘導体 |
| DE19825804C2 (de) | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| AU5194999A (en) | 1998-08-07 | 2000-02-28 | Takeda Chemical Industries Ltd. | Benzothiepin derivatives, process for the preparation of the same and uses thereof |
| ATE226448T1 (de) | 1998-12-23 | 2002-11-15 | Searle Llc | Kombinationen von ileumgallensäuretransports inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen |
| KR20010102964A (ko) | 1998-12-23 | 2001-11-17 | 윌리암스 로저 에이 | 심장혈관 징후를 위한 회장 담즙산 수송 억제인자 및피브린산 유도체의 조합물 |
| CA2356422C (en) | 1998-12-23 | 2008-09-16 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
| EA200100704A1 (ru) | 1998-12-23 | 2002-02-28 | Джи.Ди.Сирл Ллс | Комбинация для применения по сердечно-сосудистым показаниям |
| CN1338945A (zh) | 1998-12-23 | 2002-03-06 | G·D·瑟尔有限公司 | 适用于心血管疾病的回肠胆汁酸转运抑制剂和胆汁酸螯合剂组合 |
| CN1195748C (zh) | 1999-02-12 | 2005-04-06 | G.D.瑟尔有限公司 | 具有作为回肠胆汁酸转运和牛磺胆酸摄取抑制剂活性的新的1,2－苯并硫氮杂 |
| DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
| US6287609B1 (en) | 1999-06-09 | 2001-09-11 | Wisconsin Alumni Research Foundation | Unfermented gel fraction from psyllium seed husks |
| CA2400021A1 (en) | 2000-02-18 | 2001-08-23 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| HK1052183A1 (zh) | 2000-03-10 | 2003-09-05 | Pharmacia Corporation | 制造tetrahydrobenzothiepines的方法 |
| WO2001068096A2 (en) | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| TWI241195B (en) | 2000-04-10 | 2005-10-11 | Shionogi & Co | Preventive agent for bile acidic diarrhea |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| AU2001289699B2 (en) | 2000-07-28 | 2006-06-01 | Cheplapharm Arzneimittel Gmbh | New pharmaceutical composition |
| FR2812886B1 (fr) | 2000-08-08 | 2002-11-08 | Assist Publ Hopitaux De Paris | Depistage d'un nouveau syndrome hepatique et ses applications |
| SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| WO2002053548A1 (fr) | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Derives de la benzothiazepine |
| US6506921B1 (en) | 2001-06-29 | 2003-01-14 | Virginia Tech Intellectual Properties, Inc. | Amine compounds and curable compositions derived therefrom |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| CN1582151A (zh) | 2001-09-08 | 2005-02-16 | 阿斯特拉曾尼卡有限公司 | 用于治疗高脂血症、具有回肠胆汁酸转运(ibat)抑制活性的苯并硫氮杂䓬和苯并硫杂二氮杂䓬衍生物 |
| US20030199515A1 (en) | 2001-09-12 | 2003-10-23 | G.D. Searle, Llc | Method for the preparation of crystalline tetrahydrobenzothiepines |
| SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0314079D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| AU2002351752A1 (en) | 2001-12-29 | 2003-07-30 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| GB0201850D0 (en) | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
| KR100990524B1 (ko) | 2002-08-28 | 2010-10-29 | 아사히 가세이 파마 가부시키가이샤 | 신규한 4급 암모늄 화합물 |
| US7312208B2 (en) | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| WO2004108067A2 (en) | 2003-04-03 | 2004-12-16 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| WO2005082874A1 (ja) | 2004-02-27 | 2005-09-09 | Asahi Kasei Pharma Corporation | 新規なベンゾチアゼピン及びベンゾチエピン化合物 |
| TW200533336A (en) | 2004-03-02 | 2005-10-16 | Fujisawa Pharmaceutical Co | Concomitant drugs |
| EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
| TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| JP4896480B2 (ja) | 2004-10-01 | 2012-03-14 | 第一三共ヘルスケア株式会社 | 陰イオン交換樹脂の粒子状組成物 |
| WO2006121861A2 (en) | 2005-05-05 | 2006-11-16 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
| DE102005033100B3 (de) | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
| DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
| JP5072848B2 (ja) | 2005-09-20 | 2012-11-14 | ノバルティス アーゲー | 低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用 |
| WO2007120592A1 (en) | 2006-04-10 | 2007-10-25 | Merck & Co., Inc. | Cgrp antagonist salt |
| GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
| DE102006053635B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| EP2083832B1 (de) | 2006-11-14 | 2011-01-05 | Sanofi-Aventis Deutschland GmbH | Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102006053637B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DK2200588T3 (da) | 2007-09-25 | 2019-07-01 | Solubest Ltd | Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf |
| RU2011112694A (ru) | 2008-09-02 | 2012-10-10 | Юсв Лимитед (In) | Сшитые полимеры |
| JP2012509891A (ja) | 2008-11-26 | 2012-04-26 | サティオゲン ファーマシューティカルズ，インク． | 肥満症及び糖尿病を治療するための胆汁酸再循環阻害剤 |
| JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
| EP2995317A1 (en) | 2010-05-26 | 2016-03-16 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| SMT201800453T1 (it) | 2010-11-04 | 2018-11-09 | Albireo Ab | Inibitori di ibat per il trattamento delle epatopatie |
| AU2011326873B2 (en) | 2010-11-08 | 2015-02-19 | Albireo Ab | IBAT inhibitors for treatment of metabolic disorders and related conditions |
| US20120114588A1 (en) | 2010-11-08 | 2012-05-10 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
| ES2586956T3 (es) | 2010-11-08 | 2016-10-19 | Albireo Ab | Combinación farmacéutica que comprende un inhibidor de IBAT y un aglutinante de ácidos biliares |
| MX363161B (es) | 2011-10-28 | 2019-03-13 | Lumena Pharmaceuticals Inc | Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica. |
| JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| US20170143743A1 (en) | 2014-06-16 | 2017-05-25 | Valpharma International S.P.A. | Formulation for oral administration containing mesalazine |
| CN106573033A (zh) | 2014-06-25 | 2017-04-19 | Ea制药株式会社 | 固体制剂及其稳定化方法 |
| JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Ｅａファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
| US9684018B2 (en) | 2014-11-19 | 2017-06-20 | Texas Instruments Incorporated | Current sense circuit that operates over a wide range of currents |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
-
2014
- 2014-10-24 EP EP14190290.8A patent/EP3012252A1/en not_active Withdrawn
-
2015
- 2015-10-23 WO PCT/EP2015/074573 patent/WO2016062848A1/en not_active Ceased
- 2015-10-23 RU RU2017114109A patent/RU2017114109A/ru unknown
- 2015-10-23 US US15/519,808 patent/US10183920B2/en active Active
- 2015-10-23 EP EP21167339.7A patent/EP3904344A1/en not_active Withdrawn
- 2015-10-23 AU AU2015334883A patent/AU2015334883B2/en active Active
- 2015-10-23 JP JP2017519487A patent/JP6700263B2/ja active Active
- 2015-10-23 EP EP15784385.5A patent/EP3209649B1/en active Active
- 2015-10-23 CN CN201580055918.9A patent/CN107001301A/zh active Pending
- 2015-10-23 KR KR1020177012754A patent/KR102498539B1/ko active Active
- 2015-10-23 CA CA2959760A patent/CA2959760C/en active Active
- 2015-10-23 ES ES15784385T patent/ES2874573T3/es active Active
- 2015-10-23 CN CN202011101686.5A patent/CN112375044A/zh active Pending
-
2018
- 2018-12-27 US US16/234,364 patent/US10519120B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017114109A3 (enExample) | 2019-04-30 |
| AU2015334883A1 (en) | 2017-03-23 |
| JP2017537061A (ja) | 2017-12-14 |
| EP3209649B1 (en) | 2021-04-21 |
| US20190177286A1 (en) | 2019-06-13 |
| CN107001301A (zh) | 2017-08-01 |
| WO2016062848A1 (en) | 2016-04-28 |
| CA2959760A1 (en) | 2016-04-28 |
| KR20170072908A (ko) | 2017-06-27 |
| CA2959760C (en) | 2023-10-10 |
| ES2874573T3 (es) | 2021-11-05 |
| US20170240516A1 (en) | 2017-08-24 |
| CN112375044A (zh) | 2021-02-19 |
| EP3012252A1 (en) | 2016-04-27 |
| EP3209649A1 (en) | 2017-08-30 |
| US10183920B2 (en) | 2019-01-22 |
| US10519120B2 (en) | 2019-12-31 |
| KR102498539B1 (ko) | 2023-02-09 |
| JP6700263B2 (ja) | 2020-05-27 |
| AU2015334883B2 (en) | 2019-10-24 |
| EP3904344A1 (en) | 2021-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017114109A (ru) | Кристаллические модификации элобиксибата | |
| JP2017537061A5 (enExample) | ||
| RU2015150039A (ru) | Кристаллическая модификация | |
| TWI822738B (zh) | 用於製備1,5-苯并噻氮呯化合物之方法 | |
| CN107250149A (zh) | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 | |
| CN103119051B (zh) | 罗库溴铵的制备方法 | |
| US20240287108A1 (en) | nSMASE2 INHIBITOR PRODRUGS WITH ENHANCED ORAL AND BRAIN EXPOSURES | |
| US20230312561A1 (en) | Solid forms of (z)-methyl 3-(((4-(n-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxo-2,3-dihydro-1h-pyrrolo[2,3-b]pyridine-6-carboxylate and salts thereof | |
| HK1243401B (en) | Crystal modifications of elobixibat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HE9A | Changing address for correspondence with an applicant |